China Biologic names Gao CEO
This article was originally published in Scrip
Plasma-based biopharmaceutical company China Biologic has appointed its current chair, David Gao, to the additional post of CEO. Mr Gao joined China Biologic in 2011 when BMP Sunstone Corporation, for which Mr Gao served as CEO and director from 2004, was acquired by Sanofi. He succeeds Colin Zhao who will continue as president of the company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.